GSK completes acquisition of oncology firm TESARO in $5.1B deal

GSK said the transaction, which was announced last December 3,  “significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology”.

Read More